Consolidated Investment Group LLC Purchases 700 Shares of Stryker Corporation $SYK

Consolidated Investment Group LLC lifted its position in shares of Stryker Corporation (NYSE:SYK) by 7.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,510 shares of the medical technology company’s stock after buying an additional 700 shares during the quarter. Consolidated Investment Group LLC’s holdings in Stryker were worth $4,158,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Vanguard Group Inc. boosted its position in Stryker by 1.1% during the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after purchasing an additional 361,136 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after purchasing an additional 1,021,496 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Stryker by 13.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after purchasing an additional 261,058 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Stryker by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after purchasing an additional 83,954 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Stryker by 1.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock valued at $750,223,000 after purchasing an additional 30,329 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 1.1%

Shares of NYSE:SYK opened at $370.59 on Friday. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The stock has a market cap of $141.68 billion, a price-to-earnings ratio of 49.08, a PEG ratio of 2.64 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The business has a 50-day moving average price of $382.81 and a 200-day moving average price of $378.92.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same period last year, the business posted $2.81 earnings per share. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio is 44.50%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SYK shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a research report on Saturday, September 27th. Redburn Partners set a $420.00 price objective on Stryker in a research report on Thursday, September 18th. Needham & Company LLC increased their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Finally, Truist Financial set a $415.00 price target on Stryker and gave the company a “hold” rating in a research note on Monday, August 4th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $430.33.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.